Small CD4 Mimetics Prevent HIV-1 Uninfected Bystander CD4+ T Cell Killing Mediated by Antibody-dependent Cell-mediated Cytotoxicity  by Richard, Jonathan et al.
EBioMedicine 3 (2016) 122–134
Contents lists available at ScienceDirect
EBioMedicine
j ourna l homepage: www.eb iomed ic ine.comResearch aperPSmall CD4 Mimetics Prevent HIV-1 Uninfected Bystander CD4+ T Cell
Killing Mediated by Antibody-dependent Cell-mediated CytotoxicityJonathan Richard a,b,1, Maxime Veillette a,b,1, Shilei Ding a,b, Daria Zoubchenok a,b, Nirmin Alsahaﬁ a,k,
Mathieu Coutu a,b, Nathalie Brassard a, Jongwoo Park c, Joel R. Courter c, Bruno Melillo c, Amos B. Smith III c,
George M. Shaw d, Beatrice H. Hahn d, Joseph Sodroski e,f,g, Daniel E. Kaufmann a,h,i,j, Andrés Finzi a,b,k,⁎
a Centre de Recherche du CHUM, Montreal, QC H2X 0A9, Canada
b Department of Microbiology, Infectiology and Immunology, Université de Montréal, Montreal, QC H2X 0A9, Canada
c Department of Chemistry, School of Arts and Sciences, University of Pennsylvania, Philadelphia, PA 19104-6323, USA
d Departments of Medicine and Microbiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104-6076, USA
e Department of Cancer Immunology and AIDS, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA
f Department of Microbiology and Immunobiology, Division of AIDS, Harvard Medical School, Boston, MA 02115, USA
g Department of Immunology and Infectious Diseases, Harvard School of Public Health, Boston, MA 02115, USA
h Ragon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology, and Harvard, Cambridge, MA 02139-3583, USA
i Department of Medicine, Université de Montréal, Montreal, QC H3C 3T5, Canada
j Center for HIV/AIDS Vaccine Immunology and Immunogen Discovery, The Scripps Research Institute, La Jolla, CA 92037, USA
k Department of Microbiology and Immunology, McGill University, Montreal, QC H3A 2B4, Canada⁎ Corresponding author at: Centre de Recherche du CH
E-mail address: andres.ﬁnzi@umontreal.ca (A. Finzi).
1 Contributed equally.
http://dx.doi.org/10.1016/j.ebiom.2015.12.004
2352-3964/© 2015 The Authors. Published by Elsevier B.Va b s t r a c ta r t i c l e i n f oArticle history:
Received 19 October 2015
Received in revised form 7 December 2015
Accepted 8 December 2015
Available online 9 December 2015Human immunodeﬁciency virus type 1 (HIV-1) infection causes a progressive depletion of CD4+ T cells. Despite
its importance for HIV-1 pathogenesis, the precisemechanismsunderlying CD4+T-cell depletion remain incom-
pletely understood. Here wemake the surprising observation that antibody-dependent cell-mediated cytotoxic-
ity (ADCC) mediates the death of uninfected bystander CD4+ T cells in cultures of HIV-1-infected cells.
While HIV-1-infected cells are protected from ADCC by the action of the viral Vpu and Nef proteins, uninfected
bystander CD4+T cells bind gp120 shed from productively infected cells and are efﬁciently recognized by
ADCC-mediating antibodies. Thus, gp120 shedding represents a viral mechanism to divert ADCC responses to-
wards uninfected bystander CD4+ T cells. Importantly, CD4-mimetic molecules redirect ADCC responses from
uninfected bystander cells to HIV-1-infected cells; therefore, CD4-mimetic compounds might have therapeutic
utility in new strategies aimed at speciﬁcally eliminating HIV-1-infected cells.
© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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Human immunodeﬁciency virus (HIV) infection causes the progres-
sive loss of CD4+ T cells, which leads to acquired immunodeﬁciency
syndrome (AIDS) and death. Despite its clinical importance, the precise
mechanism(s) underlying CD4+T cell depletion duringHIV-1 infection
remains poorly understood (Thomas, 2009; Grossman et al., 2002;
Mccune, 2001). HIV replication is known to directly induce the death
of infected CD4+T cells (Hazenberg et al., 2000; Cummins and
Badley, 2014) by a plethora of mechanisms, including envelope
glycoprotein-mediated cytotoxicity, apoptosis via activation of CaspasesUM, QC H2X 0A9, Canada.
. This is an open access article underand DNA damage responses (Sodroski et al., 1986; Lifson et al., 1986;
Cao et al., 1996; Labonte et al., 2003; Cooper et al., 2013; Sainski et al.,
2011). Themassive depletion of CD4+T cells in SHIV-infectedmonkeys
has been shown to depend, at least in part, on themembrane-fusing ca-
pacity of the viral envelope glycoproteins (Etemad-Moghadam et al.,
2001). In addition, HIV-speciﬁc CD8+ cytotoxic T cells also play a
major role in eliminating HIV-infected cells (Mcmichael and Rowland-
Jones, 2001). However, the mechanisms of uninfected bystander
CD4+ T cell death and the contribution of this process to HIV-1 patho-
genesis are not well understood. It has been described that uninfected
CD4+ T cells die from apoptosis induced by over-expression of several
death ligands (Cummins and Badley, 2014), activation-induced cell-
death caused by a state of hyper-inﬂammation (Alimonti et al., 2003),
direct cytotoxicity mediated by some HIV proteins including Tat, Vpr,
Nef and gp120 (Varbanov et al., 2006), and caspase-1-dependentthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Doitsh et al., 2014; Monroe et al., 2014). In fact, killing of uninfected
CD4+T cells was estimated to account for the high rate of turnover of
CD4+ T cells in HIV-infected individuals (Mccune et al., 2000; Mohri
et al., 2001;Meyaard et al., 1992;Matrajt et al., 2014). However, no par-
ticular mechanism has been identiﬁed that could account for this short
half-life.
The HIV-1 envelope glycoprotein (Env) trimer is derived from pro-
teolytic cleavage of a trimeric gp160 precursor (Allan et al., 1985;
Robey et al., 1985) and is composed of gp120 exterior and gp41 trans-
membrane subunits. The gp120 exterior subunit is retained on the tri-
mer via labile, non-covalent interactions with the gp41 ectodomain.
This results in spontaneous dissociation of gp120 from gp41, known
as gp120 shedding (Helseth et al., 1991; Yang et al., 2003; Finzi et al.,
2010). Accordingly, signiﬁcant levels of soluble gp120 were found in
blood and tissues of HIV-infected individuals (Santosuosso et al.,
2009; Oh et al., 1992; Rychert et al., 2010). Interestingly, it has been sug-
gested that shed gp120 bound to the surface of lymphocytes could serve
as an effective target for immune destruction by patient antibodies and
effector cells and that this could contribute to lymphocyte destruction
in HIV-1-infected individuals (Lyerly et al., 1987). During HIV entry,
the gp120 glycoprotein is responsible for interactionswith the initial re-
ceptor, CD4 (Dalgleish et al., 1984; Klatzmann et al., 1984). CD4 induces
conformational changes in Env that expose the binding site for the che-
mokine co-receptors (CCR5 or CXCR4) (Alkhatib et al., 1996; Choe et al.,
1996; Deng et al., 1996; Dragic et al., 1996; Feng et al., 1996). We re-
cently reported that gp120–CD4 interaction in an infected cell also re-
sults in exposure of antibody-dependent cell-mediated cytotoxicity
(ADCC) epitopes recognized by antibodies present in sera,
cervicovaginal ﬂuids and breast milk from HIV-infected individuals. In-
terestingly, recognition of gp120–CD4 complexes at the surface of in-
fected (Richard et al., 2015; Veillette et al., 2014b, 2015a) or gp120-
coated (Batraville et al., 2014; Richard et al., 2014) cells results in
ADCC-mediated killing.
Here we investigated whether antibody recognition of shed gp120
bound to the surface CD4 of bystander cells results in ADCC-mediated
killing. To this end, we developed a FACS-based assay to measure the
relative killing of infected CD4+T cells versus their uninfected counter-
parts by ADCC-mediating antibodies and HIV+ sera. We observed that
HIV-1-infected cells were protected from ADCC, whereas bystander
cells were highly sensitive to killing mediated by CD4-induced (CD4i)
antibodies and HIV+ sera. This difference in susceptibility to ADCC
was due to differences in Env conformation in the two contexts. In in-
fected cells, trimeric Env remained in its unbound conformation
(i.e., shielding ADCC-mediating epitopes) due to the action of the HIV-
1 Vpu and Nef proteins, which limit the surface expression of Env–
CD4 complexes (Richard et al., 2015; Veillette et al., 2014b, 2015a,
2016). By contrast, in bystander CD4+ T cells, shed gp120 was bound
to CD4 on the cell surface, resulting in a more open Env conformation
that exposed ADCC-mediating epitopes. This raises the intriguing possi-
bility that gp120 shedding may represent a viral mechanism to divert
cytotoxic immune responses to uninfected cells. Importantly, we dem-
onstrate here that small CD4-mimetic compounds (CD4mc) protect by-
stander cells by blocking gp120 binding to uninfected CD4+ T cells,
while sensitizing HIV-infected cells to ADCC-mediated killing.
2. Materials and Methods
2.1. Cell Lines and Isolation of Primary Cells
293T human embryonic kidney (obtained from ATCC), CEM.NKr
cells (obtained from Dr. David Evans, Harvard Medical School) and pri-
mary cells were grown as previously described (Richard et al., 2010;
Veillette et al., 2014b). CD4 T lymphocytes were puriﬁed from resting
PBMCs by negative selection and activated as previously described
(Richard et al., 2015).2.2. Viral Production, Infections, Ex Vivo Ampliﬁcation and Detection of In-
fected Cells
Vesicular stomatitis viruses G (VSVG)-pseudotyped viruses allowed
equivalent levels of infection for the different viruses used, including the
D368R Env variant, and were produced and titrated as previously de-
scribed (Veillette et al., 2015a). Viruses were then used to infect
CEM.NKr cells or primary CD4+ T cells from healthy donors by spin in-
fection at 800 g for 1 h in 96-well plates at 25 °C. In order to expand
endogenously-infected CD4+T cells, primary CD4+T cellswere isolat-
ed from PBMCs obtained from viremic HIV-1-infected individuals. Puri-
ﬁed CD4+ T cells were activated with PHA-L at 10 μg/ml for 36 h and
then cultured for 6 to 8 days in RPMI-1640 complete medium supple-
mented with rIL-2 (100 U/ml).
Detection of GFP+ or p24+ infected cells was performed as previ-
ously described (Richard et al., 2015). Cells infected with the SHIV-
CH505 virus were stained intracellularly for SIVmac p27 using the
Cytoﬁx/Cytoperm Fixation/Permeabilization Kit, followed by a 2F12
anti-p27 mAb primary staining (10 μg/ml) and a goat anti-mouse
Alexa Fluor 647 secondary antibody staining (1:250 dilution). The per-
centage of infected cells (GFP+, p24+ or p27+ cells) was determined
by gating the living cell population based on the viability dye staining
(Aqua Vivid, Invitrogen).
2.3. Antibodies and Sera
The following Abs were used as ﬁrst Ab for cell-surface staining:
1 μg/ml mouse anti-CD4 mAb OKT4 (14-0048-82; eBiosciences),
5 μg/ml human anti-HIV-1 Env mAbs 2G12 (AB002; Polymun), PGT-
151 (kindly provided by P. Poignard, The Scripps Research Institute,
La Jolla, CA), A32, C11, 7B2 (kindly provided by J. Robinson, Tulane
University, NewOrleans), F240,M785-U1 andN10-U1 (kindly provided
by G. K. Lewis, University of Maryland), whereas 1 μg/ml either
goat anti-mouse Alexa Fluor-594, goat anti-human Alexa Fluor 647 or
goat anti-human Alexa Fluor 594 mAbs (Invitrogen) was used as a
secondary Ab, and AquaVivid (Invitrogen) was used as a viability
dye. The anti-SIVmac p27 antibody was puriﬁed from SIVmac p27 Hy-
bridoma (55-2F12, NIH AIDS Reagent) (Higgins et al., 1992) using
Protein A-Sepharose beads (GE, USA) according to the manufacturer's
protocol.
Sera from HIV-infected and healthy donors were collected, heat-
inactivated and conserved as previously described. Written informed
consent was obtained from all study participants [theMontreal Primary
HIV Infection Cohort (Fontaine et al., 2009, 2011) and the Canadian Co-
hort of HIV Infected Slow Progressors (Peretz et al., 2007; Kamya et al.,
2011; International et al., 2010)], and research adhered to the ethical
guidelines of CRCHUM and was reviewed and approved by the
CRCHUM institutional review board (ethics committee). All sera were
heat-inactivated for 30 min at 56 °C and stored at 4 °C until ready to
use in subsequent experiments. A random number generator
(GraphPad, QuickCalcs) was used to randomly select a number of sera
for each experiment.
2.4. Plasmids and Site-directed Mutagenesis
pNL43-ADA(Env)-GFP.IRES.Nef proviral vectors (wt or expressing
the D368R Env variant) and the VSV G-encoding plasmid (pSVCMV-
IN-VSV-G) were previously described (Veillette et al., 2015a).
The pNL43-GFP.IRES.Nef provirus encoding the NL43 X4-tropic Env
was generated by inserting the NL43 Env into pNL43-ADA(Env)-
GFP.IRES.Nef using SalI and BamHI restrictions sites, as previously
described (Veillette et al., 2014b). The plasmid encoding the HIV-1
transmitted founder (T/F) IMC CH77 was previously described
(Ochsenbauer et al., 2012; Bar et al., 2012; Parrish et al., 2013;
Fenton-May et al., 2013; Richard et al., 2015).
124 J. Richard et al. / EBioMedicine 3 (2016) 122–1342.5. Flow Cytometry Analysis of Cell-surface Staining and ADCC Responses
Cell-surface staining was performed as previously described
(Richard et al., 2015; Veillette et al., 2015a). Binding of HIV-1-infected
cells by either sera (1:1000 dilution) or mAbs (5 μg/ml) was performed48–72 h after in vitro infection or at 6–8 days post activation for
endogenously-infected ex-vivo-ampliﬁed cells, at 37 °C. Samples were
analyzed on a LSRII cytometer (BD Biosciences, Mississauga, ON,
Canada) and data analysis was performed using FlowJo vX.0.7 (Tree
Star, Ashland, OR, USA).
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viously described assay (Veillette et al., 2014b; Richard et al., 2014)
after 48–72 h of in vitro infection using a 1:1000 ﬁnal concentration
of serum or 5 μg/ml mAbs and an Effector: Target ratio of 10:1
(1 × 106 PBMC:1 × 105 CEM.NKr cells). The percentage of cytotoxicity
was calculated with the following formula for either infected or unin-
fected cells populations: (relative cell counts in Targets plus Effectors)−
(relative cell counts in Targets plus Effectors plus A32 or serum) /
(relative cell counts in Targets), as described (Richard et al., 2014,
2015; Veillette et al., 2015a).
2.6. Co-culture Assay
Activated primary CD4 T cells were stained with the eFluor-450 cell
marker (1:500 dilution, eBiosciences) for 15 min at room temperature
and washed twice with complete RPMI-1640 media before being co-
cultured with autologous infected cells (in vitro infection for 72 h) at a
ratio of 1 fresh cell to 2 infected cells in the presence or absence of
10 μg/ml VRC01 Fab or 50 μM of the CD4-mimetic compound JP-III-48
(Fig. S1) (Richard et al., 2015). Co-cultures were performed with or
without transwells (3 μm pore size, Corning, NY, USA), infected cells
were loaded in the upper chamber of the transwell and the uninfected
cells were placed in the bottom chamber. For every time point of the
co-culture assays, transwells were carefully removed and discarded
where applicable and aliquots of the co-cultured cells were distributed
in 96-well V-bottom plates and surface stained as described above.
2.7. Statistical Analyses
Statistics were analyzed using GraphPad Prism version 6.01
(GraphPad, San Diego, CA, USA). Every data set was tested for statistical
normality and this information was used to apply the appropriate
(parametric or nonparametric) statistical test. p Values b 0.05were con-
sidered signiﬁcant; signiﬁcance values are indicated as *p b 0.05,
**p b 0.01, ***p b 0.001, ****p b 0.0001.
3. Results
3.1. ADCC-mediating Antibodies Recognize Uninfected Bystander Cells
Env interaction with the CD4 receptor at the surface of infected cells
is critical for efﬁcient ADCC activity mediated bymonoclonal antibodies
targeting CD4i Env epitopes (Veillette et al., 2014b) or by sera fromHIV-
1-infected individuals (Richard et al., 2015; Veillette et al., 2015a). HIV-
1 has evolved a sophisticated mechanism to avoid ADCC by decreasing
the overall amount of cell-surface Env via Vpu-mediated BST-2 down-
regulation (Veillette et al., 2014b; Arias et al., 2014; Alvarez et al.,
2014) and Nef and Vpu-mediated CD4 downregulation from the cell
surface (Veillette et al., 2014b, 2015a). To determine whether uninfect-
ed CD4+T cells could be recognized by these antibodies, we infected
primary CD4+ T cells with a previously-reported wild-type (wt) HIV-
1 strain that encodes all accessory proteins as well as a gfp reporter
gene and an R5-tropic (ADA) envelope (Veillette et al., 2014b). Thus,
in this system, GFP+ cells are HIV-1-infected. Seventy-two hours
post-infection, cells were incubated with A32, a well-known ADCC-Fig. 1. ADCC-mediating antibodies and sera from HIV-1-infected individuals efﬁciently recogniz
mock-infected or infected with NL4-3 GFP ADA based virus, either wild-type (wt) or expressin
from 5 uninfected individuals. Shown in (a,c) are (left) dot blots depicting representative st
(b) Correlation between the levels of infection and recognition of uninfected bystander (GFP−
mAb. (d) Cell-surface staining of primary CD4+ T cells infected with an X4-tropic virus (NL4-
Shown in (left) are dot blots depicting representative staining and (right)MFI for all tested sera.
after activationwith autologous sera. Shown in (left) and (center) are dot blots depicting repres
Fluorescence Intensity (MFI) values obtainedwith all individuals. Error bars indicate themean±
aHolm–Sidak post-test, (d) an unpaired t test, (e) a Kruskal–Walliswith aDunn's post-test and (mediating CD4i antibody that recognizes an epitope located on the
gp120 inner domain Layers 1 and 2. The A32 epitope is occluded in
the unbound Env trimer but becomes exposed upon CD4 binding
(Veillette et al., 2014b). As previously reported, mock-infected cells
were not recognized by A32. The GFP+ cells infected with wild-
type HIV-1 were recognized inefﬁciently by A32; previous studies
showed that this poor recognition is due to efﬁcient down-
modulation of CD4, which permits Env to remain in its unbound con-
formation (Veillette et al., 2014b). In contrast, uninfected (GFP−)
CD4+T cells were efﬁciently recognized by the A32 antibody (Fig.
1A). We hypothesized that the exposure of CD4i epitopes on the
GFP− cells was due to the binding of shed gp120 to cell-surface
CD4. To test this possibility, we infected cells with an Env variant
that contained an alteration in the CD4 binding site (D368R) that ab-
rogates CD4 binding (Richard et al., 2014; Veillette et al., 2014a,
2015a). Interestingly, for the D368R variant, neither infected
(GFP+) nor uninfected (GFP−) cells were recognized by A32 (Fig.
1A). These data support a model in which gp120 shed from the in-
fected cell binds uninfected CD4+ T cells, resulting in gp120 confor-
mational changes that expose CD4i epitopes, including those
recognized by A32. Importantly, 2G12, an antibody that binds the
outer domain of the gp120 and is not affected by gp120–CD4 interac-
tion (Veillette et al., 2014b), did recognize D368R-infected (GFP+)
cells, indicating that the lack of recognition observed with A32 was
not due to decreased expression of the Env D368R variant (Fig. S2).
As expected, we observed a strong positive correlation between the
levels of infection and recognition of uninfected bystander (GFP−)
CD4+ T cells by A32, (Fig. 1B), suggesting that bystander cell recog-
nition by A32 depends on the amount of productive infection.
We next evaluated sera fromHIV-1-infected and uninfected individ-
uals (Supplemental Table 1). Similar to the results obtained with the
A32 antibody, more uninfected cells (GFP−) were recognized by
HIV+ sera than infected (GFP+) cells (Fig. 1C, upper panels). Sera
from uninfected individuals did not recognize infected (GFP+) or unin-
fected (GFP−) cells (Fig. 1C, lower panels). To evaluate whether this
phenotype was related to the viral strain used, we infected cells with a
transmitted/founder HIV-1 (CH77) as well as an X4-tropic virus
(Figs. 1D and S3). In both cases, uninfected bystander cells were efﬁ-
ciently recognized by HIV+ sera (Fig. 1D). To rule out any contribution
of themethod used to infect the cells, we puriﬁed primary CD4+ T cells
from six viremic HIV-1-infected individuals. Cells were activated with
PHAand then cultured in the presence of rIL-2. Six to eight days after ac-
tivation, viral replication was measured by intracellular p24 staining
and Env detected at the surface of p24+ cells with autologous sera. Of
note, infected (p24+) cells presented signiﬁcantly lower amounts of
CD4 at their surface compared to uninfected bystander (p24−) cells,
suggesting that these individuals have viruses coding for functional
Nef and Vpu proteins (Fig. S4). Under these conditions, recognition of
uninfected (p24−) cells isolated from HIV+ donors was signiﬁcantly
higher than cells from an uninfected individual (Fig. 1E). We note that
in some patients, uninfected bystander (p24−) cells were better recog-
nized than infected (p24+) cells; however, this was not always the
case. This variation could be due to the concentration of CD4-induced
antibodies present in the sera. Of note, we obtained similar results
using a SHIV infectious molecular clone (Fig. S5). Thus, independentlye uninfected bystander CD4+ T cells. Cell-surface staining of primary CD4+ T cells either
g D368R Env with (a,b) A32 mAbs or (c) sera from 10 HIV-1-infected individuals and sera
aining and (right) mean ﬂuorescence intensities (MFI) obtained for multiple stainings.
) (depicted in gray) and infected (GFP+) CD4+ T cells (depicted in green) by the A32
3 GFP) and a primary HIV-1 isolate (CH77) with sera from 10 HIV-1-infected individuals.
(e) Cell-surface staining of primaryCD4+T cells isolated from6HIV-1-infected individuals
entative staining obtained for two different HIV-1-infected individuals, and (right)Median
SEM. Statistical signiﬁcancewas tested using (a,c) an ordinary one-way ANOVA test with
b) a Spearman rank correlation (**p b 0.01, ***pb 0.001, ****p b 0.0001, ns: not signiﬁcant).
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culture are efﬁciently recognized by ADCC-mediating Abs.
3.2. Shed gp120 is the Major Source of Env at the Surface of Bystander
CD4+ T Cells
Theoretically, in addition to shed soluble gp120, gp120 detected at
the surface of bystander cells could result from the attachment of defec-
tive viral particles or from abortive infections. To evaluate the relative
contribution of viral particles compared to shed gp120, we infected pri-
mary CD4+ T cells and determined Env recognition on infected
(GFP+) and uninfected (GFP−) cells with a panel of anti-Env (anti-
gp120 and anti-gp41) antibodies. Unlike gp120, the gp41 transmem-
brane glycoprotein cannot be shed; therefore, gp41 detection on unin-
fected bystander CD4T+ cells could result from the attachment of
viral particles. As shown in Fig. 2, CD4i Abs A32 and C11 (an antibody
that binds to the gp120 β-sandwich and N- and C-termini) (Robinson
et al., 1992; Moore et al., 1994) recognized bystander (GFP−) sig-
niﬁcantly better than infected (GFP+) cells whereas the CD4-
independent 2G12 antibody recognized both cell populations equiva-
lently. This is consistent with a model in which the lack of CD4 at the
cell surface of infected cells allows Env to remain in its unboundFig. 2. Shed gp120 represents themajor source of Env present on the surface of uninfected bysta
ADAwt virus with anti-Env Abs (A32, C11, 2G12, F240 and PGT151). Shown in (a) are dot blots
presented in A as fold binding over mock. (c) Quantiﬁcation of cell-surface staining of primary
binding over mock. Statistical signiﬁcance was tested using the Mann–Whitney t test (*p b 0.0conformation; by contrast, in uninfected bystander cells, which have
higher levels of CD4 (Fig. S4), gp120 samples the CD4-bound conforma-
tion, exposing CD4i epitopes. Interestingly, we observed that a panel of
anti-gp41 antibodies or antibodies targeting the interface between the
gp120 and gp41 (PGT151) recognized infected cells more efﬁciently
than bystander cells (Figs. 2 and S6). These results suggest that the ma-
jority of Env detected on bystander cells originates from shed gp120.
3.3. Productively Infected Cells are the Source of gp120 Found onUninfected
Bystander CD4+ T Cells
Following Env detection on uninfected bystander cells over time, we
observed an increased recognition by anti-gp120 Abs over the course of
the infection, which could be explained by the increased percentage of
infected cells; recognition by anti-gp41 antibodies minimally increased
over the same time period (Fig. 3A and B). These results are consistent
with our conclusion that the recognition of bystander cells by anti-
gp120 antibodies results from soluble gp120 originating from produc-
tively infected cells. To conﬁrm this, we designed a co-culture system
that allowed the distinction of productively-infected cells from unin-
fected cells. Brieﬂy, primary CD4+ T cells were infected with our GFP-
reporter wild-type virus. The cell proliferation dye eFluor-450 wasnder cells. (a,b) Cell-surface staining of primary CD4+ T cells infectedwith the NL4-3 GFP
depicting a representative staining obtained 72 h post-infection. (b) Quantiﬁcation of data
CD4+ T cells infected with CH77 with anti-Env Abs (A32, C11, F240 and PGT151), as fold
5, **p b 0.01, ***p b 0.001, ****p b 0.0001, ns: not signiﬁcant).
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to the infected cells (eFluor-450− cells). The detection of autologous
uninfected bystander CD4+ T cells, designated as eFluor-450+GFP−
cells (Fig. 3C, top left squares), by anti-Env Abs was then evaluated by
FACS (Fig. 3C and 3D). Similar to the results in Fig. 2, uninfected by-
stander cells were recognized very efﬁciently by anti-gp120 Abs but
not by anti-gp41 Abs, conﬁrming that the major source of bound
gp120 originated from shed gp120 and not from viral particles
(Fig. 3). As expected, no recognition of uninfected bystander cells was
observed for cells co-culturedwithmock-infected cells. In this assay, by-
stander eFluor-450+cellswere not directly infected; gp120was detect-
ed on these cells only after a 24-h co-culture with productively infected
cells. These results support amodel inwhich productively-infected cells
are the main source of shed gp120 that becomes bound to bystander
CD4+ T cells.
3.4. Cell-to-cell Contact Does not Contribute to gp120 Attachment to By-
stander CD4+ T Cells
HIV-1 spreads not only by cell-free virus infection but also by cell-to-
cell transmission through the virological synapse (Jolly et al., 2004; Jolly
and Sattentau, 2004). However, it is not known whether this mecha-
nism is also involved in gp120 acquisition by bystander CD4+ T cells.
To explore the contribution of cell-to-cell transmission to bystander
gp120 coating, we added a transwell component to the co-culture sys-
tem described above. Primary CD4+ T cells were infected with wild-
type GFP-reporter virus and then added to the top chamber and co-
cultured with uninfected CD4+ T cells pre-stained with eFluor-450
for 48 h. This system minimizes cell-to-cell contact and therefore any
gp120 detected in eFluor-450-stained bystander cells must result from
shed gp120. As shown in Fig. 4, the use of transwell chambers decreased
infection and replication of HIV-1 in eFluor-450-stained autologous pri-
mary CD4+T cells. Thiswas expected since under these co-culture con-
ditions, virological synapse formation and thus transmission between
infected and eFluor-450-stained uninfected cells is signiﬁcantly re-
duced; (Jolly et al., 2004; Jolly and Sattentau, 2004). However, gp120
coating of eFluor-450-stained bystander cells was unaffected (Fig. 4),
indicating that cell-to-cell contact and virological synapse formation is
not necessary for gp120 coating of uninfected bystander cells.
3.5. Recognition of gp120 on the Surface of Bystander CD4+ T Cells Results
in ADCC-mediated Killing
To evaluate whether recognition of uninfected bystander CD4+ T
cells by ADCC-mediating antibodies and sera from HIV-1-infected indi-
viduals translated into elimination by ADCC, CEM.NKr cells infected
with NL4-3 ADA GFP wt virus were used as target cells, while PBMCs
fromhealthy HIV-negative individuals were used as effector cells. As re-
ported for primary CD4+ T cells, uninfected CEM.NKr cells were efﬁ-
ciently recognized by A32 mAbs and HIV+ sera in the context of R5-
tropic, X4-tropic or primary HIV-1 isolate viruses (Fig. S6 and data not
shown). The total number of ADCC-mediated killing (either infected
(GFP+) or uninfected bystander (GFP−)) was measured by a FACS-
based assay that uses a ﬁxed number of ﬂow-cytometry particles to nor-
malize cell counts (Richard et al., 2014). Consistentwith their enhanced
recognition by ADCC-mediating antibodies and sera from HIV-1-
infected individuals, uninfected (GFP−) bystander CD4+T cells were
signiﬁcantly more sensitive to ADCC killing mediated by both A32
or HIV+ sera than infected (GFP+) cells or mock-infected cells
(Fig. 5). Analysis of the absolute number of cells being killed by
ADCC indicates that uninfected bystander (GFP−) cells accounted
for more than 83% (in the case of A32) and 93% (for HIV+ sera) of
the cells killed (Fig. S7). As expected, pre-incubation of target cells
with an A32 Fab fragment protected uninfected bystander cells from
ADCC-mediated killing mediated by the A32 Abs (Fig. 5C). Altogether,
these results suggest that, in this system, uninfected bystander CD4+T cells are eliminated by ADCC more efﬁciently than HIV-1-infected
CD4+ T cells.
3.6. CD4mc Block Recognition of Bystander CD4+ T Cells by ADCC-
mediating Antibodies
Since soluble gp120 binds uninfected bystander CD4+ T cells
through CD4 interaction (Fig. 1A and C), we asked whether ligands
targeting the gp120 CD4-binding site could decrease gp120 interaction
with bystander cells. To this end, a Fab fragment of a very potent and
broadly-neutralizing CD4-binding site antibody (VRC01) (Wu et al.,
2010; Zhou et al., 2010) or a small CD4-mimetic compound (CD4mc),
JP-III-48 (Fig. S1), was added at the time of co-culture between infected
and eFluor-450-stained bystander cells. JP-III-48 belongs to the CD4mc
family, the prototype of which, NBD-556, was found in a screen formol-
ecules able to block gp120–CD4 binding (Zhao et al., 2005); JP-III-48 has
been previously shown to sensitize HIV-1-infected cells to ADCC
(Richard et al., 2015). Interestingly, both ligands that interact near the
CD4-binding site of gp120 were able to drastically reduce gp120 inter-
action with uninfected bystander CD4+ T cells by HIV+ sera and A32
(Figs. 6A–B and S8). However, only JP-III-48 was able to expose CD4i
epitopes recognized by HIV+ sera on infected cells (Fig. 6C), in agree-
ment with recent ﬁndings (Richard et al., 2015). Differences in this re-
gard between VRC01 Fab and JP-III-48 are likely due to the fact that
VRC01 does not induce Env conformational changes that result in the
exposure of Env CD4i epitopes (Zhou et al., 2010), whereas JP-III-48
does (Madani et al., 2014; Richard et al., 2015). Therefore, small
CD4mc such as JP-III-48, while blocking gp120 coating and recognition
of bystander CD4+ T cells by ADCC-mediating antibodies, expose
HIV-1-infected cells to ADCC-mediating killing.
4. Discussion
HIV-1 infection causes a massive depletion of CD4+ T cells. This de-
crease results from direct viral replication and subsequent death of in-
fected cells but also from indirect mechanisms that result in the killing
of uninfected, bystander, CD4+ T cells (Cummins and Badley, 2014;
Mccune, 2001; Mccune et al., 2000). This was not only observed in
HIV-infected humans but also in SHIV-infected macaques (Matrajt
et al., 2014).
Here we investigated whether ADCC contributes to bystander
CD4+T cell killing in a cell culture model. We observed that while
HIV-1-infected cells are only inefﬁciently detected by ADCC-mediating
antibodies and HIV+ sera, uninfected bystander CD4+T cells are high-
ly recognized by these antibodies; importantly, this translates into
ADCC-mediated killing. The differences in antibody recognition result
from distinct Env conformations, which are exposed depending on the
ability of HIV-1 to remove CD4 from the cell surface. In the absence of
CD4 on the surface of infected cells, Env remains in its unbound confor-
mation and does not present epitopes recognized by CD4i ADCC-
mediating antibodies (Veillette et al., 2014b). However, when shed
gp120 binds the CD4 receptor on the surface of bystander CD4+ T
cells, the bound glycoprotein samples the CD4-bound conformation
and exposes ADCC-mediating epitopes. This is independent from viral
coreceptor usage andwas observed using a variety of HIV-1 variants in-
cluding one X4, one R5, one transmitted/founder virus and a SHIV infec-
tious molecular clone. The latter observation indicates that SHIV-
infected macaques could represent an animal model to study ADCC-
mediated bystander CD4+ T cell depletion in vivo (Matrajt et al.,
2014). Altogether, our data suggest the possibility that recognition of
bystander CD4+ T cells by ADCC-mediating antibodies is a conserved
mechanism used by HIV-1 to divert ADCC responses to uninfected
cells, resulting in the protection of HIV-1-infected cells from ADCC and
other Fc-mediated effector functions (Veillette et al., 2015b).
Several studies have previously shown that in-vitro-coated gp120–
CD4+ T cells are susceptible to ADCC killing (Richard et al., 2014;
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Fig. 4. Cell-to-cell transmission is not required for the presence of gp120 on the surface of bystander cells. Uninfected cells, stainedwith the cellular dye eFluor 450, were co-culturedwith
unstained autologousmock-infected cells orwithHIV-1-infected cells, either in the context or not of a transwell system. The ability of the anti-EnvAbA32 to recognize uninfected bystand-
er cells, designated as eFluor-450+GFP− cells, was evaluated by FACS after (a) 24 h and (b) 48 h of co-culture. Shown in the top panels are the gating strategy and a representative stain-
ing obtained with the A32 Ab. Shown in the bottom panels are the quantiﬁcation of the results obtained with 5 donors. Error bars indicate the mean ± SEM. Statistical signiﬁcance was
tested using a Kruskal–Wallis with a Dunn's post-test (**p b 0.01, ns: not signiﬁcant).
129J. Richard et al. / EBioMedicine 3 (2016) 122–134Batraville et al., 2014; Baum et al., 1996; Bonsignori et al., 2012; Ferrari
et al., 1994, 2011; Gooneratne et al., 2015; Hober et al., 1995; Lambotte
et al., 2009, 2013; Lin et al., 1998). However, in the majority of these
studies, the amount of gp120 used to coat target CD4+ T cells was
well above the maximum amount of gp120 found at the surface of in-
fected cells (approximately 50 ng of gp120/million CEM-NKr cells)
(Richard et al., 2014) and the estimated quantities of soluble gp120
present in blood from HIV-1-infected individuals (Rychert et al., 2010;
Santosuosso et al., 2009). Here we did not use recombinant gp120; in-
stead, we infected cells and showed that the quantity of gp120 naturally
shed from these cells is sufﬁcient to coat bystander cells. Under these
conditions, the amount of gp120 present on the surface of bystander
cells was sufﬁcient to sensitize them to ADCC enabled by ADCC-Fig. 3. Shed gp120 from productively infected cells is the major source of gp120 present on the
CD4+ T cells infected with (a) NL4-3 GFP ADA wt virus or (b) CH77, by anti-gp120 Abs (A32
depicted in blue) over the course of the infection. The data presented are representative of th
the cellular dye eFluor 450, were co-culturedwith unstained autologousmock-infected or HIV-1
uninfected bystander cells, designated as eFluor-450+GFP− cells, was evaluated by FACS at 0, 2
obtainedwith the A32 Ab. Shown in (d) are the quantiﬁcation of the results obtainedwith at lea
Whitney t test (*p b 0.05, **p b 0.01, ns: not signiﬁcant).mediating antibodies and sera from HIV-1-infected but not from unin-
fected individuals. Importantly, we analyzed the source of the gp120
present on the surface of bystander cells using a panel of anti-Env anti-
bodies (both anti-gp120 and anti-gp41 antibodies). This analysis sug-
gested that the majority of gp120 bound on the surface of bystander
cells resulted from gp120 shedding from productively HIV-1-infected
cells rather than attached virions. Of note, cell-to-cell contact between
productively-HIV-1-infected cells and bystander cells did not appear
to contribute to gp120 coating on bystander cells, reinforcing the notion
that shedding is themainmechanism contributing to the attachment of
gp120 to the surface of bystander CD4+ T cells.
Howmight ADCC contribute to CD4+T-cell destruction in vivo, par-
ticularly in light of differences in the tissue distribution of CD4+ T cellssurface of uninfected bystander CD4+ T cells. Detection of uninfected bystander primary
, C11, 2G12; depicted in red) and anti-gp41 (F240) and anti-gp120-gp41 Abs (PGT151;
e results obtained in cells from at least two donors. (c,d) Uninfected cells, stained with
-infected cells. The ability of anti-Env Abs (A32, C11, 2G12, F240 and PGT151) to recognize
4 and 48 h of co-culture. Shown in (c) are the gating strategy and a representative staining
st 4 donorswith all tested anti-Env Abs. Statistical signiﬁcancewas tested using theMann–
Fig. 5. Uninfected bystander cells can be eliminated by ADCC. CEM.NKr cells infected with the NL4-3 ADA GFPwt virus were used as target cells in our FACS-based ADCC assays. Shown in
(a) are dot blots depicting the cell count and ﬂow cytometry particle count (bottom left) of a representative ADCC killing experiment with A32 mAb and serum from an HIV-1-infected
individual. (b) Percentage of ADCC killing obtained with the A32 mAb in 6 independent experiments. (c) Percentage of ADCC-mediated killing of uninfected bystander (GFP−) cells
with the A32 mAb in the presence or absence of the A32 Fab fragment. (d) Percentage of ADCC-mediated killing obtained with sera from 22 HIV-1-infected individuals. Error bars
indicate the mean ± SEM. Statistical signiﬁcance was tested using (b,d) an ordinary one-way ANOVA test with a Holm–Sidak post-test or (c) a Mann–Whitney t test (*p b 0.05,
**p b 0.01, ****p b 0.0001).
130 J. Richard et al. / EBioMedicine 3 (2016) 122–134and natural killer (NK) cells, the mediators of ADCC? HIV-1 replication
primarily happens in lymphoid tissues, where up to 95% of CD4+ T
cells reside (Pantaleo et al., 1994), yet only a small fraction of ADCC-
competent CD56dimCD16+ NK cell population is distributed
within lymph nodes (Luteijn et al., 2011). We hypothesize that NK
cells contribute to bystander killing during the transit of CD4+ T cells
between lymph nodes, the lymphatic system and the blood, where
CD56dimCD16+NK cells are present in large quantities and couldmedi-
ate efﬁcient ADCC against gp120-coated cells (Artis and Spits, 2015;
Fauci et al., 2005). Supporting this hypothesis, an inverse correlation be-
tween the percentage of resting CD4+T cells presenting gp120 at their
surface and the number of CD4+ T cells in the blood was recently re-
ported (Suzuki et al., 2014). Moreover, an association between T cell
dysfunction and the presence of IgG at the surface of CD4+ T cells in in-
fected individuals was previously reported (Daniel et al., 1996).
In addition to providing a potential mechanism of in vivo CD4 T cell
bystander killing, our results also have practical implications. The factFig. 6. CD4-binding site ligands abrogate recognition of bystander CD4+ T cells. Uninfected ce
mock-infected cells orwithHIV-1-infected cells in the absence or presence of the CD4-mimetic J
cells, designed as eFluor-450+GFP− cells, was evaluated by FACS after (a) 24 h and (b) 48 h o
Shown in the bottom panels are the quantiﬁcation of the results obtainedwith 8HIV+ sera usin
3 ADA GFPwt virus with sera fromHIV-1-infected individuals, in presence of the CD4mc JP-III-4
ing. Shown in the right panel is the quantiﬁcation of the results obtainedwith 6 different HIV+
Whitney t test (**p b 0.01, ***p b 0.001, ns: not signiﬁcant).that uninfected bystander cells coated with HIV-1 gp120 expose CD4i
epitopes and thus are highly susceptible to ADCC can inﬂuence
in vitro measurement of ADCC responses. Indeed, in vitro ADCC assays
that rely on measurements made on the total cell population or on NK
cell activation cannot distinguish ADCC responses targeting HIV-
infected cells versus ADCC directed against bystander cells. This could
result in an overestimation of the ADCC-mediating activity of CD4i Abs
such as A32, which targets gp120-coated bystander cellsmore efﬁcient-
ly than infected cells.
In addition to its role in sensitizing bystander CD4+ T cells to ADCC,
the presence of gp120 at the surface of these cells could also alter differ-
ent immune functions. The presence of soluble gp120 in infected
individuals has been shown to be associated with higher levels of IL-6,
IL-10, and TNF-α; gp120 binding to CD4+T cellsmodulates the expres-
sion of several cytokines, whichmay contribute to the reduced immune
function of CD4+T cells observed in HIV-1-infected individuals (Guo
et al., 2012; Rychert et al., 2010). Moreover, the binding of shed gp120lls, stained with the cellular dye eFluor 450, were co-cultured with unstained autologous
P-III-48 or VRC01 Fab fragment. The ability of HIV+ sera to recognize uninfected bystander
f co-culture. Shown in the top panels are the gating strategy and a representative staining.
g 4 different CD4+T-cell donors. (c) Staining of primary CD4 T cells infectedwith theNL4-
8 or VRC01 Fab fragment. Shown on the left are histograms depicting representative stain-
sera. Error bars indicate themean± SEM. Statistical signiﬁcancewas tested using aMann–
131J. Richard et al. / EBioMedicine 3 (2016) 122–134
132 J. Richard et al. / EBioMedicine 3 (2016) 122–134to CD4 on uninfected bystander cells and the subsequent presentation
of CD4i epitopes likely also generates CD4-induced Abs, which are com-
monly found in HIV-1 infected individuals. For example, analysis of the
frequency of B cells producing anti-Env Abs in HIV-1 acutely infected
subjects revealed that N47% of cells produced CD4i Abs (Robinson
et al., 2005; Decker et al., 2005). Our results showing ADCC-mediated
killing of bystander cells by CD4i antibodies raise the intriguing possibil-
ity that in untreated HIV-1-infected individuals, the concentration of
these antibodies might inﬂuence the rate of CD4 T-cell depletion and
disease progression. It is also possible that the presence of other
ADCC-mediating antibodies that do not require the CD4-bound confor-
mation of Env to recognize infected cells might help control viral repli-
cation and transmission (Milligan et al., 2015; Baum et al., 1996; Forthal
et al., 1999; Ljunggren et al., 1990; Mabuka et al., 2012). Finally, it has
been shown that NK cells from HIV-infected individuals exhibit an al-
tered phenotype, subset distribution and effector functions (Fauci
et al., 2005). It is thus conceivable that recognition of shed gp120 on un-
infected bystander cells could contribute to the sustained activation of
NK cells and the subsequent perturbation of NK-cell functions. In that
context, recent ﬁndings suggested that sustained stimulation of NK
cells by anti-HIV or anti-CD16 Abs has the potential to impair NK cell
function, via attenuation of NKp46-dependent signals (Parsons et al.,
2014).
We recently reported that, in addition to their direct antiviral effect
(Madani et al., 2008) and sensitization of HIV-1 viral particles to neu-
tralization (Madani et al., 2014), small CD4mc such as JP-III-48 sensitize
HIV-1-infected cells to ADCC (Richard et al., 2015). Here we extend the
antiviral properties of these compounds to protecting uninfected by-
stander CD4+ T cells from gp120 attachment and recognition by
HIV+ sera and ADCC-mediating Abs. Although antibodies directed at
the CD4-binding site could also decrease attachment of gp120 to by-
stander cells, they do not increase recognition of HIV-1-infected cells
by HIV+ sera and therefore do not focus ADCC responses on HIV-1-
infected cells like CD4mc. As CD4+T cells are essential for the immuno-
logic control of HIV, any therapy decreasing the rapid turnover of by-
stander cells could help preserve CD4+ T cells and therefore enable
additional immunological mechanisms and/or curative approaches
aimed at eradicating HIV. Therefore, by protecting bystander CD4+ T
cells from killing while sensitizing HIV-1-infected cells to ADCC,
CD4mc might prove to have therapeutic utility in approaches aimed at
speciﬁcally eliminating HIV-1-infected cells.
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